Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-VOLVO: Dapagliflozin on Volume Status in Heart Failure
NCT04869124Phase 4Completed
- Start
- Feb 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure (HF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in relative plasma volume status at 12 weeks. Started Feb 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04869124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04869124.